B and T lymphocyte associatedGenealiases: BTLA1 · CD272
Q-omics provides the consensus-scored BTLA profile across patient tissues and cancer cell-line models. BTLA expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, BTLA is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, BTLA RNA expression shows 16,102 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, COAD, and LSCC as cancer lineages where BTLA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BTLA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BTLA survival associations across molecular data types. BTLA RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BTLA RNA expression–survival associations across cancer types. High BTLA expression shows favorable associations in HNSC, SKCM, CESC, OV, LUAD and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for BTLA RNA expression.
This table summarizes BTLA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for BTLA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BTLA shows lower tumor expression in COAD, LUSC and UCEC and higher tumor expression in KIRC, LUAD and STAD. The COAD box plot shows higher BTLA RNA expression in normal versus tumor tissue (log2 FC = −0.938, t-test p < 0.001).
This table shows molecular features associated with BTLA in patient tissues and cancer cell lines. In patient samples, BTLA shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BTLA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LUNG_NSCLC_LUAD.
